146 related articles for article (PubMed ID: 35817438)
1. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
Wang Z; Yong Chan EC
Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
[TBL] [Abstract][Full Text] [Related]
2. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
Leow JWH; Gu Y; Chan ECY
Eur J Pharm Sci; 2023 Aug; 187():106475. PubMed ID: 37225005
[TBL] [Abstract][Full Text] [Related]
3. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
Leow JWH; Verma RK; Lim ABH; Fan H; Chan ECY
Eur J Pharm Sci; 2021 Sep; 164():105889. PubMed ID: 34044117
[TBL] [Abstract][Full Text] [Related]
4. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control.
Leow JWH; Chan ECY
Pharmacol Ther; 2024 Jun; 258():108637. PubMed ID: 38521247
[TBL] [Abstract][Full Text] [Related]
5. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
Tang LWT; Wu G; Chan ECY
J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
[TBL] [Abstract][Full Text] [Related]
6. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.
Zhao T; Chen Y; Wang D; Wang L; Dong P; Zhao S; Wang C; Meng Q; Sun H; Liu K; Wu J
Cardiovasc Drugs Ther; 2022 Feb; 36(1):121-129. PubMed ID: 33411110
[TBL] [Abstract][Full Text] [Related]
7. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids.
Karkhanis A; Tram NDT; Chan ECY
Biochem Pharmacol; 2017 Dec; 146():188-198. PubMed ID: 28958841
[TBL] [Abstract][Full Text] [Related]
8. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
Evangelista EA; Kaspera R; Mokadam NA; Jones JP; Totah RA
Drug Metab Dispos; 2013 Dec; 41(12):2087-94. PubMed ID: 24021950
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline derivatives inhibit cardiac CYP2J2.
Kim JS; Arango AS; Shah S; Arnold WR; Tajkhorshid E; Das A
J Inorg Biochem; 2022 Apr; 229():111722. PubMed ID: 35078036
[TBL] [Abstract][Full Text] [Related]
10. Arachidonic Acid Metabolism by Human Cardiovascular CYP2J2 Is Modulated by Doxorubicin.
Arnold WR; Baylon JL; Tajkhorshid E; Das A
Biochemistry; 2017 Dec; 56(51):6700-6712. PubMed ID: 29200270
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.
Xu L; Chen LY
Sci Rep; 2020 Dec; 10(1):22267. PubMed ID: 33335233
[TBL] [Abstract][Full Text] [Related]
12. Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner.
Lee E; Wu Z; Shon JC; Liu KH
Drug Metab Dispos; 2015 Aug; 43(8):1250-3. PubMed ID: 26048912
[TBL] [Abstract][Full Text] [Related]
13. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
Lu J; Liu D; Zhou X; Chen A; Jiang Z; Ye X; Liu M; Wang X
Phytomedicine; 2018 Jan; 39():137-145. PubMed ID: 29433675
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.
Ikemura N; Yamaori S; Kobayashi C; Kamijo S; Murayama N; Yamazaki H; Ohmori S
Chem Biol Interact; 2019 Jun; 306():1-9. PubMed ID: 30965050
[TBL] [Abstract][Full Text] [Related]
15. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel substrates for human cytochrome P450 2J2.
Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
[TBL] [Abstract][Full Text] [Related]
17. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
Karkhanis A; Lam HY; Venkatesan G; Koh SK; Chai CL; Zhou L; Hong Y; Kojodjojo P; Chan EC
Biochem Pharmacol; 2016 May; 107():67-80. PubMed ID: 26972388
[TBL] [Abstract][Full Text] [Related]
18. Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review.
Wiley AM; Yang J; Madhani R; Nath A; Totah RA
Drug Metab Rev; 2024; 56(2):145-163. PubMed ID: 38478383
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of human cytochrome P450 2J2 and its ligands].
Ma HY; Ning J; Ge GB; Yang L; Hao DC
Yao Xue Xue Bao; 2017 Jan; 52(1):26-33. PubMed ID: 29911373
[TBL] [Abstract][Full Text] [Related]
20. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
Park SW; Heo DS; Sung MW
Cell Oncol (Dordr); 2012 Feb; 35(1):1-8. PubMed ID: 21656078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
